Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.
So we are extremely glad to present our work on small triple negative breast cancers at as and basically what we did was looking at what is the prognosis and what is the um the use of chemotherapy and benefit of use of chemotherapy in this population. And and the reason we focus on this category of tumors is that it's pretty frequent, like up to one third of all triple negative breast cancer is diagnosed at this early stage. And still there is not much innovation in this population because usually patients with stage one triple negative breast cancer are excluded from clinical trials and innovations like immunotherapy inhibitors are really didn't reach the stage one population. And so we look at this population in database and we obstructed data for 8600 patients with multiple negative breast cancers. And what we found out was that chemotherapy is mostly used in patients that are tumors are uh higher than five millimeters. So patients with T one B and T one C tumor and actually the use of chemotherapy increase between 2010 and 2019 by about 10% in these populations also, we found that there are some predictors of increased use of chemotherapy such as younger age of the patient, uh ductal of the tumor, higher grade and higher size of the tumor, and also my status of the patient. And finally, when you look at the prognosis, you see that in, in patients with uh microscopic infiltration or T one A so up to five millimeters, triple negative breast cancer, there really seems to be no major difference in breast cancer specific survival uh depending on chemo received. And also in patients with two where there are T one bs up to one centimeter. There really is not uh a major difference. But when you look at T one CS between one and two centimeters, you really see a relevant difference in five year breast cancer specific survival of more than 3% suggesting a benefit in this population. And now we hope to uh further pursue this project by looking at the biology of the multiple negative breast cancers and hopefully also start prospective trials to, to bring innovative drugs to patients with multiple negative breast cancers and also to improve the tolerability of adjuvant treatment for this population.
